Polypharmacy in Pediatrics: Modern Conditions
https://doi.org/10.15690/vsp.v18i3.2039
Abstract
The polypharmacy as the reason of iatrogeny is topical problem of health care both in Russia and in the world. Clinical aspects of polypharmacy come out as pharmacotherapy efficiency decrease and development of severe adverse drug effects as well as health care cost increase. There is no uniform definition of polypharmacy in pediatric practice. However quantity and duration of medicine administration, medicine class, medicine eligibility, medical conditions and clinical conditions are usually considered. The correlations between existing medicines prescription models and health problems in children appears relevant. The results of recent researches on this problem are presented in the review.
Supporting agencies: Not specified.
About the Authors
Natalia B. Lazareva
Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Disclosure of interest: contributor confirmed the absence of a reportable conflict of interests
Russian Federation
Disclosure of interest: contributor confirmed the absence of a reportable conflict of interests
Evgenia V. Shikh
Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Disclosure of interest: works in collaboration with Pfizer Innovations LLC, receives fees for lecturing
Russian Federation
Disclosure of interest: works in collaboration with Pfizer Innovations LLC, receives fees for lecturing
Ekaterina V. Rebrova
Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Disclosure of interest: contributor confirmed the absence of a reportable conflict of interests
Russian Federation
Disclosure of interest: contributor confirmed the absence of a reportable conflict of interests
Anastasia Yu. Ryazanova
Volgograd State Medical University
Russian Federation
Disclosure of interest: contributor confirmed the absence of a reportable conflict of interests
Russian Federation
Disclosure of interest: contributor confirmed the absence of a reportable conflict of interests
References
1. Sychev DA, Otdelеnov VA, Krasnova NM, Ilyina ES. Polypragmasy: a clinical pharmacologist’s view. Ter Arkh. 2016;88(12):94–102. (In Russ). doi: 10.17116/terarkh2016881294-102.
2. Duerden M, Avery T, Payne R. Polypharmacy and medicines optimisation: Making it safe and sound. The King’s Fund; 2013. Available from: www.kingsfund.org.uk/sites/files/kf/field/ field_publication_file/polypharmacy-and-medicines-optimisationkingsfund-nov13.pdf.
3. Friend DG. Polypharmacy — multiple-ingredient and shotgun prescriptions. N Engl J Med. 1959;260(20):1015–1018. doi: 10.1056/NEJM195905142602005.
4. PubMed: NCBI [Internet]. US National Library of Medicine National Institutes of Health. Available from: https://www.ncbi.nlm. nih.gov/pubmed/.
5. Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatrics. 2017;17(1):230. doi: 10.1186/s12877-017-0621-2.
6. Order № 575n Ministry Of Health Russia «Ob utverzhdenii poryadka okazaniya meditsinskoy pomoshchi po profilyu “klinicheskaya farmakologiya”», dated 2012 November 2. (In Russ). Доступно по: http:// www.rosminzdrav. ru/documents/5534-prikaz-minzdrava-rossiiot-2-noyabrya-2012-g-575n. Ссылка активна на 15.01.2019.
7. Morden NE, Goodman D. Pediatric polypharmacy: time to lock the medicine cabinet? Arch Pediatr Adolesc Med. 2012;166(1): 91–92. doi: 10.1001/archpediatrics.2011.162.
8. Feudtner C, Dai D, Hexem KR, et al. Prevalence of polypharmacy exposure among hospitalized children in the United States. Arch Pediatr Adolesc Med. 2012;166(1):9–16. doi: 10.1001/ archpediatrics.2011.161.
9. Chen H, Patel A, Sherer J, Aparasu R. The definition and prevalence of pediatric psychotropic polypharmacy. Psychiatr Serv. 2011;62(12):1450–1455. doi: 10.1176/appi.ps.000642011.
10. DosReis S, Zito JM, Safer DJ, et al. Multiple psychotropic medication use for youths: a two-state comparison. J Child Adolesc Psychopharmacol. 2005;15(1):68–77. doi: 10.1089/ cap.2005.15.68.
11. Morrato EH, Dodd S, Oderda G, et al. Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid Population, 1998–2003. Clin Ther. 2007; 29(1):183–195. doi: 10.1016/j.clinthera.2007.01.002.
12. Bakaki PM, Horace A, Dawson N, et al. Defining pediatric polypharmacy: a scoping review. PLoS ONE. 2018;13(11):e0208047. doi: 10.1371/journal.pone.0208047.
13. Feinstein JA, Feudtner C, Valuck RJ, Kempe A. The depth, duration, and degree of outpatient pediatric polypharmacy in Colorado fee-for-service medicaid patients. Pharmacoepidemiol Drug Saf. 2015;24:1049–1057. doi: 10.1002/pds.3843.
14. Wright R, Sloane R, Pieper C, et al. Underuse of indicated medications among physically frail older US veterans at the time of hospital discharge: results of a cross-sectional analysis of data from the Geriatric Evaluation and Management Drug Study. Am J Geriatr Pharmacother. 2009;7(5):271–280. doi: 10.1016/j.amjopharm.2009.11.002.
15. Magro L, Moretti U, Leone R. Epidemiology and characteristics of adverse drug reactions caused by drug-drug interactions. Expert Opin Drug Saf. 2012;11(1):83–94. doi: 10.1517/14740338.2012.631910.
16. Astrand B. Avoiding drug-drug interactions. Chemotherapy. 2009;55(4):215–220. doi: 10.1159/000218100.
17. Nekrasova YeA, Goryushkina AA. Sravnitel’nyy analiz riska mezhlekarstvennogo vzaimodeystviya u patsiyentov terapevticheskogo i khirurgicheskogo profilya. Materialy 73-y otkrytoy nauchno-prakticheskoy konferentsii molodykh uchonykh i studentov VolGMU s mezhdunarodnym uchastiyem «Aktual’nyye problemy eksperimental’noy i klinicheskoy meditsiny»; dated 2015 April 22–23. Volgograd; 2015. рр. 370–371. (In Russ).
18. Sergeyeva VM, Prival’tseva NS. Otsenka riska mezhlekarstvennogo vzaimodeystviya u patsiyentov kardiologicheskogo otdeleniya statsionara g. Volgograda. Materialy 73-y otkrytoy nauchno-prakticheskoy konferentsii molodykh uchonykh i studentov VolGMU s mezhdunarodnym uchastiyem «Aktual’nyye problemy eksperimental’noy i klinicheskoy meditsiny»; dated 2015 April 22–23. Volgograd; 2015. Р. 309. (In Russ.)
19. Mogayzel PJ, Jr, Naureckas ET, Robinson KA, et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2013;187(7):680–689. doi: 10.1164/rccm.201207-1160oe.
20. Horace AE, Ahmed F. Polypharmacy in pediatric patients and opportunities for pharmacists’ involvement. Integr Pharm Res Pract. 2015;4:113–126. doi: 10.2147/IPRP.S64535.
21. Feudtner C, Dai D, Hexem KR, et al. Prevalence of polypharmacy exposure among hospitalized children in the United States. Arch Pediatr Adolesc Med. 2012;166(1):9–16. doi: 10.1001/ archpediatrics.2011.161.
22. Nguyen JK, Fouts MM, Kotabe SE, Lo E. Polypharmacy as a risk factor for adverse drug reactions in geriatric nursing home residents. Am J Geriatr Pharmacother. 2006;4(1):36–41. doi: 10.1016/j.amjopharm.2006.03.002.
23. Joshua L, Devi P, Guido S. Adverse drug reactions in medical intensive care unit of a tertiary care hospital. Pharmacoepidemiol Drug Saf. 2009;18(7):639–645. doi: 10.1002/pds.1761.
24. Gogou M, Giannopoulos A, Haidopoulou K. Polypharmacy in children hospitalized due to respiratory problems: data from a university hospital [abstracts]. Conference: ERS International Congress; 2018. doi: 10.1183/13993003.congress-2018.PA1349.
25. Kulichenko TV, Baybarina EN, Baranov A.A, et al. Pediatric Health quality assessment in different regions of Russian Federation. Annals of the Russian Academy of Medical Sciences. 2016;71(3):214–223. (In Russ). doi: 10.15690/vramn688.
26. Mukhortova SA. Audit i podderzhivayushchij monitoring kak instrument povysheniya kachestva statsionarnoj meditsinskoj pomoshchi detyam v regionakh Rossijskoj Federatsii: na primere Rostovskoj oblasti. [dissertation abstract] Moscow: FGAU «Natsional’nyj meditsinskij issledovatel’skij tsentr zdorov’ya detej» Minzdrava Rossii; 2017. 25 р. (In Russ). Доступно по: https://search.rsl.ru/ru/ record/01008712581.Ссылка активна на 14.04.2019.
27. Mukhortova SA, Kulichenko TV, Namazova-Baranova LS, et al. Supportive supervision as a technology of improving the quality of hospital care delivery. Pediatric pharmacology. 2017;14(3):192–197. (In Russ). doi: 10.15690/pf.v14i3.1744.
28. Gudkov RA. Comedication in the structure of drug burden in children in hospital. Vestnik RUDN. Meditsina. 2016;(4):60–67. (In Russ.)
29. Dosreis S, Yoon Y, Rubin DM, et al. Antipsychotic treatment among youth in foster care. Pediatrics. 2011;128(6):e1459–1466. doi: 10.1542/peds.2010-2970.
30. Spencer D, Marshall J, Post B, et al. Psychotropic medication use and polypharmacy in children with autism spectrum disorders. Pediatrics. 2013;132(5):833–840. doi: 10.1542/peds.2012-3774.
31. Kreider AR, Matone M, Bellonci C, et al. Growth in the concurrent use of antipsychotics with other psychotropic medications in Medicaid-enrolled children. J Am Acad Child Adolesc Psychiatry. 2014;53(9):960–970. doi: 10.1016/j.jaac.2014.05.010.
32. AACAP.org. American Academy of Child and Adolescent Psychiatry. Practice parameters for the use of atypical antipsychotic medications in children and adolescents [Accessed 2015 March 2]. Available from: http://www.aacap.org/App_Themes/ AACAP/docs/practice_parameters/Atypical_Antipsychotic_ Medications_Web.pdf.
33. Toteja N, Gallego JA, Saito E, et al. Prevalence and correlates of antipsychotic polypharmacy in children and adolescents receiving antipsychotic treatment. Int J Neuropsychopharmacol. 2014;17(7):1095–1105. doi: 10.1017/S1461145712001320.
34. Jureidini J, Tonkin A, Jureidini E. Combination pharmacotherapy for psychiatric disorders in children and adolescents: prevalence, efficacy, risks and research needs. Pediatr Drugs. 2013;15(5): 377–391. doi: 10.1007/s40272-013-0032-6.
35. Feinstein JA, Feudtner C, Kempe A. Adverse drug event-related emergency department visits associated with complex chronic conditions. Pediatrics. 2014;133(6):e1575–1585. doi: 10.1542/ peds.2013-3060.
36. Feinstein JA, Feudtner C, Valuck RJ, Kempe A. The depth, duration, and degree of outpatient pediatric polypharmacy in Colorado fee-for-service Medicaid patients. Pharmacoepidemiol Drug Saf. 2015;24(10):1049–1057. doi: 10.1002/pds.3843.
37. Zemlyakova EI, Shakirova EM, Safina LZ. Expert analysis treatment of acute respiratory infection by pediatricians. Prakticheskaya meditsina. 2012;(7-1):121–125. (In Russ.)
38. Fedorov A, Salomova S. Polypragmasy in paediatrics. Pediatric pharmacology. 2009;6(5):107–109. (In Russ.)
39. Howard RF. Current status of pain management in children. JAMA. 2003;290(18):2464–2469. doi: 10.1001/jama.290.18.2464.
40. Orsey AD, Belasco JB, Ellenberg JH, et al. Variation in receipt of opioids by pediatric oncology patients who died in children’s hospitals. Pediatr Blood Cancer. 2009;52(7):761–766. doi: 10.1002/pbc.21824.
Review
For citations:
Lazareva N.B., Shikh E.V., Rebrova E.V., Ryazanova A.Yu. Polypharmacy in Pediatrics: Modern Conditions. Current Pediatrics. 2019;18(3):212-218. (In Russ.) https://doi.org/10.15690/vsp.v18i3.2039
Views:
2029
Email this article 
